The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro

N. Von Bubnoff^*, S. P. Gorantla, R. A. Engh, T. M. Oliveira, S. Thöne, E. Åberg, C. Peschel, J. Duyster

^*Korrespondierende/r Autor/-in für diese Arbeit